Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, Mathers AJ, Bassetti M, Vazquez J, Cornely OA, Solomkin J, Bhowmick T, Bishara J, Daikos GL, Felton T, Furst MJL, Kwak EJ, Menichetti F, Oren I, Alexander EL, Griffith D, Lomovskaya O, Loutit J, Zhang S, Dudley MN, Kaye KS. Wunderink RG, et al. Among authors: lomovskaya o. Infect Dis Ther. 2018 Dec;7(4):439-455. doi: 10.1007/s40121-018-0214-1. Epub 2018 Oct 1. Infect Dis Ther. 2018. PMID: 30270406 Free PMC article.
Pharmacodynamics of levofloxacin against Pseudomonas aeruginosa with reduced susceptibility due to different efflux pumps: do elevated MICs always predict reduced in vivo efficacy?
Griffith DC, Corcoran E, Lofland D, Lee A, Cho D, Lomovskaya O, Dudley MN. Griffith DC, et al. Among authors: lomovskaya o. Antimicrob Agents Chemother. 2006 May;50(5):1628-32. doi: 10.1128/AAC.50.5.1628-1632.2006. Antimicrob Agents Chemother. 2006. PMID: 16641428 Free PMC article.
Levofloxacin reduces inflammatory cytokine levels in human bronchial epithelia cells: implications for aerosol MP-376 (levofloxacin solution for inhalation) treatment of chronic pulmonary infections.
Tsivkovskii R, Sabet M, Tarazi Z, Griffith DC, Lomovskaya O, Dudley MN. Tsivkovskii R, et al. Among authors: lomovskaya o. FEMS Immunol Med Microbiol. 2011 Mar;61(2):141-6. doi: 10.1111/j.1574-695X.2010.00755.x. Epub 2010 Nov 12. FEMS Immunol Med Microbiol. 2011. PMID: 21073547 Free article.
Potency of Meropenem-Vaborbactam in Lung Surfactant.
Rubio-Aparicio D, Loutit J, Dudley M, Lomovskaya O. Rubio-Aparicio D, et al. Among authors: lomovskaya o. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e01702-17. doi: 10.1128/AAC.01702-17. Print 2018 Jan. Antimicrob Agents Chemother. 2017. PMID: 29038266 Free PMC article.
β-Lactamase inhibitors: what you really need to know.
Ambrose PG, Lomovskaya O, Griffith DC, Dudley MN, VanScoy B. Ambrose PG, et al. Among authors: lomovskaya o. Curr Opin Pharmacol. 2017 Oct;36:86-93. doi: 10.1016/j.coph.2017.09.001. Epub 2017 Oct 27. Curr Opin Pharmacol. 2017. PMID: 29096172 Review.
77 results